The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index.
Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method
Open accessAbstract
BACKGROUND: Diabetes costs represent a large burden to both patients and the health care system. However, few studies that examine the economic consequences of diabetes have distinguished between the two major forms, type 1 and type 2 diabetes, despite differences in underlying pathologies. Combining the two diseases implies that there is no difference between the costs of type 1 and type 2 diabetes to a patient. In this study, we examine the costs of type 1 diabetes, which is often overlooked due to the larger population of type 2 patients, and compare them to the estimated costs of diabetes reported in the literature. METHODOLOGY/PRINCIPAL FINDINGS: Using a nationally representative dataset, we estimate yearly and lifetime medical and indirect costs of type 1 diabetes by implementing a matching method to compare a patient with type 1 diabetes to a similar individual without the disease. We find that each year type 1 diabetes costs this country $14.4 billion (11.5-17.3) in medical costs and lost income. In terms of lost income, type 1 patients incur a disproportionate share of type 1 and type 2 costs. Further, if the disease were eliminated by therapeutic intervention, an estimated $10.6 billion (7.2-14.0) incurred by a new cohort and $422.9 billion (327.2-519.4) incurred by the existing number of type 1 diabetic patients over their lifetime would be avoided. CONCLUSIONS/SIGNIFICANCE: We find that the costs attributed to type 1 diabetes are disproportionately higher than the number of type 1 patients compared with type 2 patients, suggesting that combining the two diseases when estimating costs is not appropriate. This study and another recent contribution provides a necessary first step in estimating the substantial costs of type 1 diabetes on the U.S.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, two studies have provided cost estimates specifically for type 1 diabetes, proposing an annual figure of $14·4–14·9 billion in the USA.104,105”
From Type 1 diabetes (2014) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Strawn, L. G., Flegal, K. M., & Mei, Z. (2002) · Cited by 6,426
Matching as an econometric evaluation estimator: Evidence from evaluating a job training programme
Heckman, J. J., Ichimura, H., & Todd, P. E. (1997) · The Review of Economic Studies · doi:10.2307/2971733 · Cited by 5,486
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
2000 CDC Growth Charts for the United States: methods and development.
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Grummer‐Strawn, L. M., Flegal, K. M., Mei, Z., Wei, R. X., Curtin, L. R., Roche, A. F., & Johnson, C. L. (2002) · PubMed · Cited by 3,716
Ogden, C. L., Kuczmarski, R. J., Flegal, K. M., Mei, Z., Guo, S. S., Wei, R. X., Grummer‐Strawn, L. M., Curtin, L. R., Roche, A. F., & Johnson, C. L. (2002) · PEDIATRICS · doi:10.1542/peds.109.1.45 · Cited by 2,017
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Incidence and trends of childhood type 1 diabetes worldwide 1990–1999
The DIAMOND Project Group (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01925.x · Cited by 1,085
Flagged first, then by citations
2 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- MI Harris, 1995, Classification, diagnostic criteria, and screening for diabetes., Diabetes in America, 2, 95
Cited by
Sorted by citations
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Self-citationTeplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Self-citationZonulin, regulation of tight junctions, and autoimmune diseases
Fasano, A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06538.x · Cited by 365
Experimental Diabetes Mellitus in Different Animal Models
Al-Awar, A., Kupai, K., Veszelka, M., Szűcs, G., Attieh, Z. K., Murlasits, Z., Török, S., Pósa, A., & Varga, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9051426 · Cited by 309
de Bock, M. I., Ethel Codner, D., Craig, M. E., Huynh, T., Maahs, D. M., Mahmud, F. H., Marcovecchio, L., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13455 · Cited by 282
Metadata
- Authors
- Tao, B., Pietropaolo, M., Atkinson, M., Schatz, D., & Taylor, D.
- Affiliations
- University of Michigan (US)
- University of Florida (US)
- Center for Naval Analyses (US)
- Corresponding author
- Tao, Betty
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-07-09
- Volume
- 5
- Issue
- 7
- Pages
- e11501
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2901386
- OpenAlex
- W2093172018
- Cited by
- 197
- References
- 51
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 8 · 2023: 13 · 2022: 18 · 2021: 15 · 2020: 21 · 2019: 20 · 2018: 17 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 11 · 2013: 12 · 2012: 8
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Michigan
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK053456)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, health care costs, indirect costs, income loss, lifetime costs, economic burden, type 2 diabetes, cost comparison, economic burden of disease, cost avoidance
- MeSH terms
- Diabetes Mellitus, Type 1, Female, Humans, Male, Models, Theoretical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
